

Manufacturer	Partner	Current phase	Type/ technology	Booster Shot in Development (Y/N)	Notes
NOVAVAX	Par/Endo	Phase III	Rec. Protein Nanoparticle + adjuvant		NVX-CoV2373. (Nuvaxovid) 2-dose series. 10 dose vial. Refrigeration only. For ages 18 years and older. US secured the purchase 3.2 million doses of the vaccine upon FDA approval. Recommended for approval by the FDA's Vaccines and Related Biological Products Advisory Committee on 6/7/22. Currently under FDA review of the EUA application. Expected June 2022 approval for USA market.
SANOI PASTEUR	GlaxoSmithKline	PHASE III	Recombinant Technology + Adjuvant	Y	SCB-2019. (Vidprevtyn) Recombinant protein-based vaccine 10 mcg antigen formulation of the SARS-CoV-2 adjuvanted recombinant protein-based vaccine in combination with GSK's AS03 adjuvant. Expect a viable vaccine for approval by December of 2022 under an Emergency Use Authorization (EUA). Storage requirements of current candidate(s) is refrigeration only.
SANOI PASTEUR	GlaxoSmithKline	PHASE II	Recombinant Technology + Adjuvant		Various Booster shots currently in Phase II. Participant receive monovalent (D614) AS03 vaccine or bivalent (D614 + B.1.351)-AS03, or a single dose of the monovalent vaccine without an adjuvant.
MODERNA		Full FDA Approval	mRNA	Y	mRNA-1273 (Spikevax) 2 dose series at 100 mcg per dose Approved with an EUA by the FDA. Booster dose (50 mcg) approved Oct 2021. Vaccine stable at refrigerated temperatures of 2 to 8 degrees C for 30 days.
PFIZER	BIONTECH, ACUITAS THERAPEUTICS	Full FDA Approval	mRNA	Y	BNT162b2. (Comirnaty) 2 dose series of 30 mcg per dose. Booster shot is a 30 mcg dose. Approved by the FDA under an EUA for children ages 5-11.
J&J	Emergent Biosolutions; Merck, Takeda (for additional mfg supply)	EUA Approval	ADENOVIRUS	Y	AD26.COV2-S. 1 dose. Approved with an EUA by the FDA. Booster dose approved for adults 18 years old or older. Booster dose to be administered at least 2 months after initial dose. Storage requirements is refrigeration only.
ASTRAZENECA	OXFORD	PHASE III	ADENOVIRUS	N	AZD-1222.(Vaxzevria) Currently approved in the UK. No approval currently in the US. Current candidate can be stored at refrigerated temperatures for up to 3 months. Will require 2 doses approx 28 days apart.
SANOI PASTEUR	Translate Bio	Phase II	mRNA		MRT5500. Phase I/II trials began in March 2021 with an enrollment of 415 adults. Expected production of 90 million doses
CUREVAC	GlaxoSmithKline	PHASE I	mRNA		CV2CoV. Company now shifting focus on to 2nd generation COVID vaccine (CV2VoV) and has retired development on CVnCoV. Withdrew its application for approval from the European Medicines Agency for CVnCoV after late-stage trials results in June showed only 47% efficacy. Working on next generation of mRNA vaccine candidate with GSK.
GRITSTONE BIO		Phase I			Second-generation COVID-19 vaccine using (sam)RNA technology. Phase I clinical trial (CORAL). Aim to develop a vaccine that will use the COVID-19 spike protein and additional viral epitopes offering good targets for CD8T cell and antibody responses.
Last Updated: 7/11/22					For inquiries, please contact pharmacyquestions@vizientinc.com